---
title: "JUMPCAN: The cooperative product Marcilosavir tablets have obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249272143.md"
description: "JUMPCAN announced that its wholly-owned subsidiary has obtained the drug registration certificate from the National Medical Products Administration for the drug Marcilosavir tablets, developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd. This drug is a Class 1 new drug with broad-spectrum anti-influenza virus properties, suitable for healthy adults with uncomplicated type A and B influenza"
datetime: "2025-07-20T07:56:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249272143.md)
  - [en](https://longbridge.com/en/news/249272143.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249272143.md)
generator: "portal-rs"
---

# JUMPCAN: The cooperative product Marcilosavir tablets have obtained the drug registration certificate

According to the Zhitong Finance APP, JUMPCAN (600566.SH) announced that its wholly-owned subsidiary JUMPCAN Pharmaceutical Group Co., Ltd. (referred to as "JUMPCAN Limited") has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the development of Marcilosavir tablets in cooperation with Nanjing Zhengxiang Pharmaceutical Co., Ltd. (referred to as "Zhengxiang Pharmaceutical").

Marcilosavir tablets are a Class 1 new drug declared by Zhengxiang Pharmaceutical and are a new generation of polymerase acidic protein (PA) nucleic acid endonuclease inhibitors, characterized by broad-spectrum anti-influenza virus properties. The approved indication is for the treatment of previously healthy adults with uncomplicated type A and B influenza, excluding patients at high risk of influenza-related complications

### Related Stocks

- [600566.CN](https://longbridge.com/en/quote/600566.CN.md)

## Related News & Research

- [Biocytogen Pharmaceuticals announces extraordinary general meeting](https://longbridge.com/en/news/297148979.md)
- [Pernod Ricard Q4 Sales EUR 2.21 Bln](https://longbridge.com/en/news/297129478.md)
- [08:39 ETPredoc Launches Curated Data Layer to Make Fragmented Medical Records Usable](https://longbridge.com/en/news/297187951.md)
- [Pernod Ricard FY26 profit from recurring operations drops 17.9% to €2.42 billion; net sales fall 14.2% to €9.4 billion](https://longbridge.com/en/news/297127777.md)
- [Scandium Canada intersects 124.9 m at 232 ppm Sc2O3 at Crater Lake project in Quebec](https://longbridge.com/en/news/297227972.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**